Completed study
Official Study Title
A randomized prospective clinical trial to assess the role of PROcalcitonin-Guided antimicrobial therapy to REduce long-term infectionS Sequelae
Brief Description
PROGRESS is a randomized clinical trial aiming to test the efficacy of an algorithm of the duration of antimicrobial treatment based on serum procalcitonin in patients with sepsis on the development of resistant bowel microbiota and of infections by Clostridium difficile.
Details
Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 7 sites in Greece
Actual enrolment: 266 participants
ClinicalTrials.gov Identifier: NCT03333304
EudraCT number: 2017-002011-33
National Organization for Medicines Approval: IS 62-17
National Ethics Committee Approval: 62/17
Study Start: October 2017
Study Completion: July 2019
Condition/Disease studied: Sepsis
Keywords: Procalcitonin
Related publications
- BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial
Infectious Diseases and Therapy 2021 Sep;10(3):1437-1449 - Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial
American Journal of Respiratory and Critical Care Medicine 2021 Jan 15;203(2):202-210